Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
New method could make single-cell RNA sequencing more accessible to patients

New method could make single-cell RNA sequencing more accessible to patients

Study finds how low levels of the TET2 gene fuel rapid growth of acute myeloid leukemia

Study finds how low levels of the TET2 gene fuel rapid growth of acute myeloid leukemia

Myelodysplastic syndromes are commonly misdiagnosed, study finds

Myelodysplastic syndromes are commonly misdiagnosed, study finds

A novel pharmacology modeling approach to monitor acute lymphoblastic leukemia treatment

A novel pharmacology modeling approach to monitor acute lymphoblastic leukemia treatment

Case report and review of a novel chromosomal abnormality in AML patient

Case report and review of a novel chromosomal abnormality in AML patient

Could mutated blood cells hold the key to lower Alzheimer's risk?

Could mutated blood cells hold the key to lower Alzheimer's risk?

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Research opens door to new, more efficient drug combinations for acute myeloid leukemia

Research opens door to new, more efficient drug combinations for acute myeloid leukemia

NCI launches new initiative to test new drug combinations that target specific tumor alterations

NCI launches new initiative to test new drug combinations that target specific tumor alterations

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

Treatment with luspatercept improves red blood cell counts in patients with myelodysplastic syndromes

Treatment with luspatercept improves red blood cell counts in patients with myelodysplastic syndromes

Nonhuman primate study helps explain how stem cell transplantation can kill HIV virus

Nonhuman primate study helps explain how stem cell transplantation can kill HIV virus

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

UVA Cancer Center receives $250,000 to develop innovative new approach to treating leukemia

UVA Cancer Center receives $250,000 to develop innovative new approach to treating leukemia

Lawyer fees draw scrutiny as Camp Lejeune claims stack up

Lawyer fees draw scrutiny as Camp Lejeune claims stack up

Break Through Cancer funds AML research at MD Anderson

Break Through Cancer funds AML research at MD Anderson

New computational method identifies routes of cellular differentiation in acute myeloid leukemia

New computational method identifies routes of cellular differentiation in acute myeloid leukemia

Research findings could help inform more effective therapies for AML

Research findings could help inform more effective therapies for AML

Mitophagy helps blood cancer cells to evade the killing effects of BH3 mimetic drug

Mitophagy helps blood cancer cells to evade the killing effects of BH3 mimetic drug

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.